PDF(Pubmed)
Abstract：
UNASSIGNED: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is established in the management of pseudomyxoma peritonei (PMP), selected cases of peritoneal mesothelioma, and resectable colorectal or ovarian peritoneal metastases in Western countries. However, the efficacy and feasibility of these techniques are not well established in the Asian population, and little has been reported on long-term survival outcomes for surgically resected PMP patients.
UNASSIGNED: Retrospective analysis of a prospective database of short- and longer-term outcomes of consecutive patients who underwent CRS and HIPEC for PMP in a newly established peritoneal malignancy unit in Japan between 2010 and 2016.
UNASSIGNED: A total of 105 patients underwent CRS and HIPEC and 57 maximal tumor debulking (MTD) for pseudomyxoma peritonei. In the CRS group, the primary tumor was appendiceal in 94 patients (90%) followed by ovarian and colorectal. Major postoperative complications occurred in 22/105 patients (21%) with one in-hospital mortality (0.9%). The 5-year overall and disease-free survival rates for the CRS group were 74.2% and 50.1%, respectively. Multivariate analysis revealed unfavorable histology to be the significant predictor of reduced overall and disease-free survival. Completeness of cytoreduction, CA19-9, and CA125 were also associated with disease-free survival.
UNASSIGNED: This is the first report on long-term outcomes and survival analysis of CRS and HIPEC for PMP in the Asian population. CRS and HIPEC can be conducted with reasonable safety and favorable survival in a new center. Complete tumor removal and histological type are the strongest prognostic factors for both overall and disease-free survival.
UNASSIGNED: Retrospective analysis of a prospective database of short- and longer-term outcomes of consecutive patients who underwent CRS and HIPEC for PMP in a newly established peritoneal malignancy unit in Japan between 2010 and 2016.
UNASSIGNED: A total of 105 patients underwent CRS and HIPEC and 57 maximal tumor debulking (MTD) for pseudomyxoma peritonei. In the CRS group, the primary tumor was appendiceal in 94 patients (90%) followed by ovarian and colorectal. Major postoperative complications occurred in 22/105 patients (21%) with one in-hospital mortality (0.9%). The 5-year overall and disease-free survival rates for the CRS group were 74.2% and 50.1%, respectively. Multivariate analysis revealed unfavorable histology to be the significant predictor of reduced overall and disease-free survival. Completeness of cytoreduction, CA19-9, and CA125 were also associated with disease-free survival.
UNASSIGNED: This is the first report on long-term outcomes and survival analysis of CRS and HIPEC for PMP in the Asian population. CRS and HIPEC can be conducted with reasonable safety and favorable survival in a new center. Complete tumor removal and histological type are the strongest prognostic factors for both overall and disease-free survival.
摘要：
■在腹膜假性黏液瘤（PMP）的治疗中建立了细胞减灭术（CRS）联合腹腔热化疗（HIPEC），选定的腹膜间皮瘤病例，在西方国家可切除的结直肠或卵巢腹膜转移。然而,这些技术的有效性和可行性在亚洲人群中还没有得到很好的证实，关于手术切除的PMP患者的长期生存结局的报道很少.
■回顾性分析2010年至2016年在日本新建立的腹膜恶性肿瘤病房连续接受CRS和HIPEC治疗PMP的患者的短期和长期结局的前瞻性数据库。
■共有105例患者接受CRS和HIPEC治疗，57例腹膜假性黏液瘤最大肿瘤减积（MTD）。在CRS组中，94例(90%)患者的原发肿瘤为阑尾,其次是卵巢和结直肠.22/105例患者（21％）发生了主要的术后并发症，其中1例住院死亡率（0.9％）。CRS组的5年总体生存率和无病生存率分别为74.2%和50.1%,分别。多变量分析显示，不利的组织学是总体生存率和无病生存率降低的重要预测因素。细胞减少的完整性，CA19-9和CA125也与无病生存率相关。
■这是关于CRS和HIPEC对亚洲人群PMP的长期结果和生存分析的第一份报告。CRS和HIPEC可以在合理的安全和有利的生存在一个新的中心进行。肿瘤完全切除和组织学类型是总体生存和无病生存的最强预后因素。
■回顾性分析2010年至2016年在日本新建立的腹膜恶性肿瘤病房连续接受CRS和HIPEC治疗PMP的患者的短期和长期结局的前瞻性数据库。
■共有105例患者接受CRS和HIPEC治疗，57例腹膜假性黏液瘤最大肿瘤减积（MTD）。在CRS组中，94例(90%)患者的原发肿瘤为阑尾,其次是卵巢和结直肠.22/105例患者（21％）发生了主要的术后并发症，其中1例住院死亡率（0.9％）。CRS组的5年总体生存率和无病生存率分别为74.2%和50.1%,分别。多变量分析显示，不利的组织学是总体生存率和无病生存率降低的重要预测因素。细胞减少的完整性，CA19-9和CA125也与无病生存率相关。
■这是关于CRS和HIPEC对亚洲人群PMP的长期结果和生存分析的第一份报告。CRS和HIPEC可以在合理的安全和有利的生存在一个新的中心进行。肿瘤完全切除和组织学类型是总体生存和无病生存的最强预后因素。
